Medical surveillance for BRCA1/2 heterozygotes reduces the risk of dying from breast cancer, however it is unlikely to affect the ovarian cancer related mortality (van der Velde et al., 2009; Møller et al., 2013). Here, BRCA1 is linked to breast cancer.